Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01(B) in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

BACKGROUND: A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Jason W., Yadava, Anjali, Tosh, Donna, Sattabongkot, Jetsumon, Komisar, Jack, Ware, Lisa A., McCarthy, William F., Cowden, Jessica J., Regules, Jason, Spring, Michele D., Paolino, Kristopher, Hartzell, Joshua D., Cummings, James F., Richie, Thomas L., Lumsden, Joanne, Kamau, Edwin, Murphy, Jittawadee, Lee, Cynthia, Parekh, Falgunee, Birkett, Ashley, Cohen, Joe, Ballou, W. Ripley, Polhemus, Mark E., Vanloubbeeck, Yannick F., Vekemans, Johan, Ockenhouse, Christian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769081/
https://www.ncbi.nlm.nih.gov/pubmed/26919472
http://dx.doi.org/10.1371/journal.pntd.0004423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769081/
https://www.ncbi.nlm.nih.gov/pubmed/26919472
http://dx.doi.org/10.1371/journal.pntd.0004423

Ejemplares similares